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ABSTRACT 
Close monitoring of chemotherapy toxicity can be instrumental in ensuring prompt symptom 
management and quality care. Our aim was to develop a brief clinical tool to enable daily 
assessment of chemotherapy toxicity, and investigate/establish its content validity, 
feasibility/applicability, internal consistency and stability. Development of the Daily Chemotherapy 
Toxicity self-Assessment Questionnaire (DCTAQ) was based on an initial item pool created from two 
scoping reviews. Expert panel review (n=15) and cognitive debriefing with patients with cancer (n=7) 
was used to establish content validity. Feasibility/acceptability, applicability (self-report v. interview-
like administration), internal consistency (KR-20) and test-retest reliability (at 1-hour intervals) of the 
DCTAQ were field-tested with 82 patients with breast or colorectal cancer receiving active 
chemotherapy at eight hospitals. Initial development/content validity stages enabled item revisions 
and re-wording that led to a final, 11-item DCTAQ version with 10 core symptom items plus one 
open-ended ‘any other symptom’ item. Feasibility and acceptability were demonstrated through 
absence of participant withdrawals, absence of missing data and no complaints about tool length. 
The DCTAQ was found to have modest internal consistency (KR-20=0.56), but very good test-retest 
reliability. The DCTAQ is a brief clinical tool that allows for rapid and accurate daily assessments of 
chemotherapy toxicity in clinical practice. 
 
Keywords: Patient-reported outcomes; Cancer; Chemotherapy toxicity; Daily Chemotherapy 
Toxicity self-Assessment Questionnaire (DCTAQ); Reliability; Validity 
Running title: Development/testing of the DCTAQ 
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INTRODUCTION 
Chemotherapy is a primary treatment modality for cancer. By exerting their pharmacological 
properties on cancerous cells, chemotherapy agents can suppress tumour growth or eliminate 
residual disease. However, the likelihood for normal body cells and tissues to be affected in the 
process is always present; thus, the impact of chemotherapy toxicity (expressed as one or more 
symptoms experienced by the patient) cannot be underestimated (Yamagishi, Morita, Miyashita, & 
Kimura, 2009). Chemotherapy toxicity often leads to distressing symptoms (e.g. nausea, 
breathlessness, fever) and potentially life-threatening conditions (e.g. neutropenia), associated with 
impaired quality of life, infections, poor treatment adherence, and increased mortality (McKenzie et 
al., 2011; Saevarsdottir, Fridriksdottir, & Gunnarsdottir, 2010; Yamagishi et al., 2009), as well as 
significant costs for the healthcare system (Brearley et al., 2011). Close symptom monitoring during 
active chemotherapy is therefore considered a cornerstone of multidisciplinary oncology practice in 
order to manage symptoms promptly, prevent exacerbation or relapse, and plan care accordingly 
(Basch et al., 2016; Cleeland, 2007; Cleeland et al., 2000). 
 
Despite recent advances, including attempts to boost prediction of the risk for chemotherapy toxicity 
(Extermann et al., 2012; Hurria et al., 2011), chemotherapy-related symptoms are not always 
optimally assessed and managed in everyday clinical practice (Breivik et al., 2009; National Institute 
of Cancer, 2009). In addition, there is on-going debate about how best to generate data about 
chemotherapy-related toxicity to inform cancer clinicians. Typically, standard methods of collection of 
patient information involve the completion of paper-based forms by clinicians, using invalidated 
and/or retrospective accounts from patients. These strategies have been criticised as inefficient, 
subject to recall bias, and not representative of the patient experience (Ethan Basch et al., 2009; 
Coolbrandt et al., 2011; Fromme, Eilers, Mori, Hsieh, & Beer, 2004; Trotti, Colevas, Setser, & Basch, 
2007).  
 
In recent years, the use of patient-reported outcome (PRO) measures in routine cancer care practice 
has been advocated as a means to overcome the aforementioned limitations by facilitating a 
systematic approach that is based on the perspective of the patient (Flores et al., 2012; Gilbert, 
Sebag-Montefiore, Davidson, & Velikova, 2015; Howell et al., 2015). The use of PRO measures may 
result in the quicker reporting of symptoms through more frequent discussions with health 
professionals, improvement in the identification of bio-psychosocial problems that are often 
overlooked within routine practice, enhanced management of treatment toxicity, reduced 
hospitalisations, better adherence to chemotherapy, increased quality of life, and increased 
satisfaction with care (Basch et al., 2016; Donaldson, 2008; Kotronoulas et al., 2014; Snyder et al., 
2012; Wu & Snyder, 2011). Several PRO measures and systems, including the Patient-Reported 
Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) 
measurement system (Basch et al., 2014) and patient-reported adverse events (PRAE) system 
(Holch et al., 2016), have thus far been developed specifically to facilitate detection of chemotherapy 
toxicity (Armes et al., 2014; Brown et al., 2001; Kushner et al., 2008; Leonard et al., 2005; Postma et 
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al., 2005; Sitzia, Dikken, & Hughes, 1997). However, they collectively present with critical limitations. 
These limitations include a focus on individual symptoms (Kushner et al., 2008; Leonard et al., 2005; 
Postma et al., 2005) that fails to address the synergistic and cumulative nature of the symptom 
experience (Lenz, Pugh, Milligan, Gift, & Suppe, 1997; Miaskowski, 2004); lengthy measures that 
challenge implementation and use in busy clinical settings (Armes et al., 2014; Brown et al., 2001; 
Sitzia et al., 1997); incomplete information on the spectrum of the symptom experience (Sitzia et al., 
1997); and lack of symptoms descriptors to assist patients to accurately report their symptoms 
(Brown et al., 2001; Sitzia et al., 1997). ‘Generic’ symptom assessment measures have also been 
used in this context (Bruera, Kuehn, Miller, Selmser, & Macmillan, 1991; Cleeland et al., 2000; de 
Haes et al., 1996; Portenoy et al., 1994). These measures have been developed for general use in 
cancer care, i.e. irrespective of type of cancer, treatment or phase; thus, whether they can accurately 
capture the specifics of chemotherapy toxicity assessment and grading may be questioned.  
 
One key limitation of all available PRO measures for chemotherapy toxicity assessment is the use of 
prolonged time-frames for recall. With acute presentation and wide fluctuation in chemotherapy 
toxicity prevalence, severity and distress (Gilbert et al., 2015), even a 7-day recall window may be 
inadequate to provide accurate and relevant symptom information (Sitzia et al., 1997). In contrast, 
daily toxicity assessments can lead to a dramatic increase of the clinical relevance of symptom data 
(Gilbert et al., 2015). If facilitated through brief patient self-reports and focussed on a comprehensive 
evaluation (prevalence, severity, distress) of common chemotherapy symptoms, daily toxicity 
assessments can allow for well-informed clinical decision-making, prompt symptom management 
and over-time examination of symptom patterns to tailor patient care. The aim of this study was 
therefore to develop the Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ) as a 
novel PRO measure to enable close monitoring of chemotherapy toxicity in clinical practice, and 
generate evidence to establish its content validity, feasibility/acceptability, internal consistency, and 
test-retest reliability (stability). 
 
METHODS 
Development of a pilot DCTAQ 
The DCTAQ was developed as part of a larger research programme that evaluated clinical 
implementation of the Advanced Symptom Management System (ASyMS) (Kearney et al., 2009; 
Kearney, Maguire, Kotronoulas, & McCann, 2016) with patients with breast or colorectal cancer 
during adjuvant chemotherapy. Scale items were generated from the two scoping literature reviews 
that aimed to identify the most prevalent toxicities experienced by patients receiving chemotherapy 
for breast or colorectal cancer. In the interest of clinical relevance, the ten most prevalent symptoms 
were selected for inclusion in a pilot DCTAQ. These included nausea (feeling sick), vomiting (being 
sick), diarrhoea, constipation, sore mouth and/or throat, paraesthesia, sore hands and/or feet, flu-like 
symptoms/infection, tiredness, and pain. The pilot DCTAQ aimed to collect patients’ self-reports on 
each symptom’s prevalence, severity and associated distress. Formatting of items and response 
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options was similar to two existing symptom assessment questionnaires (de Haes et al., 1996; 
Portenoy et al., 1994).  
 
Initial development of the pilot DCTAQ was followed by a combined, collaborative approach to 
establish its content validity by involving health professionals and patients (Gravetter & Forzano, 
2012; Staniszewska, Haywood, Brett, & Tutton, 2012). Ethical approval was obtained from the Fife 
and Forth Valley Research Ethics Committee. 
 
Expert Content Review 
A multi-disciplinary expert panel of cancer clinicians was convened to review the pilot DCTAQ 
(Gravetter & Forzano, 2012), by focussing on such aspects as content, appropriateness, response 
format, and wording of the pilot DCTAQ. The expert panel included nurses (n=9; including nurse 
practitioners, nurse consultants, and Macmillan nurse consultants) and allied health professionals 
(n=6; including pharmacists, team leaders, clinical service managers, and clinical learning 
facilitators), all with extensive experience in cancer care. 
 
Cognitive Debriefing Exercise with Patients 
Feedback from expert content review was incorporated into the pilot DCTAQ. The tool was then 
submitted to a cognitive debriefing exercise (Demuro, Lewis, Dibenedetti, Price, & Fehnel, 2012) with 
seven patients with breast or colorectal cancer, who were either receiving active-phase 
chemotherapy or had received chemotherapy in the past six months. Patients completed the pilot 
DCTAQ and reviewed its content, in order to establish readability, comprehension, relevance and 
appropriateness of DCTAQ items (Gravetter & Forzano, 2012). Open-ended, closed-ended and 
probing questions were used to elicit information. All comments were recorded on pro-forma sheets.  
 
Field Testing of the DCTAQ 
Patient feedback was used to develop the final version of the DCTAQ. Field testing of the DCTAQ 
was carried out as part of the parent project. Patients eligible for participation had a histologically 
confirmed diagnosis of breast or colorectal cancer; had a plan to receive ≥4 cycles of adjuvant 
chemotherapy as in-patients or outpatients; were 18 years old or older; were able to read/write/speak 
English; were physically and psychologically fit to participate in research as determined by a member 
of the healthcare team; and were able to provide written informed consent. Recruitment took place at 
eight clinical sites across the UK. Participants completed the DCTAQ twice (test/retest) during their 
first chemotherapy cycle, with a 1-hour time interval between the two assessments. This time interval 
was considered appropriate to not only accommodate fluctuations in fast-changing symptoms, but 
also ensure that patients would not recall their initial responses. 
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Data Analysis 
Feasibility and acceptability analyses included calculation of missing values, DCTAQ-related 
withdrawals (n, %) and median time to complete the DCTAQ. Internal consistency of the DCTAQ 
was determined through calculation of item-to-item phi correlations and the Kuder-Richardson 
formula 20 (KR-20) for measures with dichotomous responses (yes/no on symptom prevalence) 
(Kuder & Richardson, 1937). Test-retest reliability of DCTAQ dichotomous responses (yes/no on 
symptom prevalence) was assessed with % of absolute agreement that indicated the proportion of 
cases where symptom prevalence was reported the same on the test and retest DCTAQ. Cohen’s 
kappa coefficients (κ value) were also calculated as they produce chance-corrected agreements 
(Dunn, 2009; Friedman & Wyatt, 2006). In addition, κ values were calculated separately by type of 
cancer, gender (colorectal cancer group only) and age (<55 v. ≥55 years based on a median-split 
approach) to further examine whether DCTAQ stability remained unaffected by such variables. By 
convention, κ values of 0.60-0.80 indicated ‘good’ agreement, κ>0.80 denoted ‘excellent’ agreement, 
and κ=1 ‘perfect’ agreement. Analyses were carried out in SPSS, v. 18 (IBM SPSS, Chicago, IL). 
 
RESULTS 
Content validity 
The expert panel was involved in 2-6 consecutive review rounds. DCTAQ items were found to be 
understandable and relevant. Panel members positively commented on DCTAQ’s brevity and 
comprehensiveness, as well as the use of a 24-hour recall period. Half of the panel members 
suggested that inclusion of descriptors/indicators of symptom severity would be beneficial to reduce 
patient confusion/misinterpretation and enhance accuracy of self-reports. If based on an existing 
taxonomy (e.g. the Common Terminology Criteria for Adverse Events [CTCAE] (National Institute of 
Cancer, 2009)), symptom severity ratings could easily be translated into routine practice and 
incorporated into current management guidelines. Such descriptors (see Overview of the DCTAQ) 
were incorporated in the pilot DCTAQ, ahead of its distribution to patients during the cognitive 
debriefing exercise.  
 
Overall, patients found DCTAQ items to be understandable, relevant, and readable. A few items had 
to be reworded to enhance clarity. For instance, three patients indicated a lack of understanding of 
the term ‘paraesthesia’. Whilst the word itself was unfamiliar, patients did understand the descriptors 
associated to this symptom. Nevertheless, the term ‘paraesthesia’ was replaced with the more 
descriptive term ‘changes in sensation in your hands and/or feet’. Moreover, four patients noted that 
they had experienced symptoms not included in the pilot DCTAQ. They would welcome the option to 
report any additional symptoms to their clinical team. As a result, an eleventh item was included to 
give the patient the option to report any additional symptoms. 
 
Page 6 of 20
European Journal of Cancer Care
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
6 
Overview of the DCTAQ 
The DCTAQ is an 11-item, self-report measure that assesses 10 core chemotherapy-related 
symptoms. Item 11 invites the patient to report “any other symptoms”. All items are set to be 
answered using a recall period of the past 24 hours. Three dimensions of chemotherapy toxicity are 
evaluated, namely symptom prevalence, symptom severity, and symptom distress. Symptom 
prevalence is reported on a dichotomous scale of yes/no for the eleven items. Where a ‘yes’ answer 
is received, the patient is asked to rate their symptom severity and symptom distress. A 3-point 
numerical scale (mild, moderate, severe) is used to evaluate symptom severity. The severity 
indicators have associated descriptors that are based on the CTCAE V4.0 taxonomy (National 
Institute of Cancer, 2009). Mild symptoms are defined using CTC 1 criteria, whilst CTC 2 criteria 
define moderate symptoms, and CTC 3 criteria define severe symptoms. Finally, a 4-point numerical 
scale (not at all, a little, quite a bit, very much) evaluates how much a patient is bothered/distressed 
by the symptom. The item relating to ‘pain’ also asks the patient to indicate the location of his/her 
pain on a body map, and whether the pain is new. Patients have the option to report up to 4 different 
areas of pain.  
 
Feasibility and acceptability 
Eighty-two patients completed the DCTAQ during the field testing. The typical participant had an 
average age of 56 years (29-75). Most participants were diagnosed with breast cancer (59.6%; 
n=48). Seven out of ten patients with colorectal cancer were diagnosed with stage III disease; for 
patients with breast cancer, stage III disease accounted for 57% of the cases (Table 1). Regardless 
of cancer type, the most frequently reported symptoms were tiredness (n=48; 58.5%) and pain 
(n=24; 30%), followed by changes in sensation in hands and/or feet (n=21; 26%). Nausea, vomiting, 
diarrhoea and constipation were the symptoms least reported in this sample (n=0-4; 0-5%). 
 
In terms of completeness of data, missing values on the DCTAQ were kept to a minimum, i.e. <1% 
of all available data. No patient commented on the length of the DCTAQ or withdrew. When asked 
whether DCTAQ items accurately captured the patient’s symptom, >90% of participants confirmed 
this across all of the DCTAQ items. Completion of the DCTAQ required 10-12 minutes of the 
patient’s time. 
 
Internal consistency 
Internal consistency analyses revealed only modest reliability for the DCTAQ. A KR-20 coefficient of 
0.56 was calculated. Item-to-item phi correlation coefficients ranged from -0.10 to 0.48. 
 
Test-retest reliability 
κ coefficients indicated a high level of agreement in the total sample, with items on diarrhoea, 
constipation, flu-like symptoms exhibiting perfect agreement (Table 2). For patients with breast 
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cancer the lowest level of agreement was for items on ‘feeling sick’ and ‘sore mouth and/or throat’, 
with κ values just above 0.60. For patients with colorectal cancer, the lowest levels of agreement 
were for ‘changes in sensation in hands and/or feet’ (κ=0.76) and ‘sore hands and/or feet’ (κ=0.77). 
 
Excellent-to-perfect agreement was found for most items based on male/female split (Table 3), 
except for ‘sore hands and/or feet’ (κ=0.63) in female participants, and ‘changes in sensation in 
hands and/or feet’ in male participants (κ=0.64). Excellent-to-perfect agreement was also found 
based on the age split. Excellent-to-perfect agreement was found in the ‘<55’ age group for all items 
where sufficient information allowed calculation of κ values. Good agreement was found in the ‘≥55’ 
age group for such items as ‘sore mouth and/or throat’ (κ=0.63 breast cancer group; κ=0.64 
colorectal group), ‘changes in sensation in hands and/or feet’ (κ=0.68 colorectal cancer group) and 
‘sore hands and/or feet’ (κ=0.60 colorectal cancer group). 
 
DISCUSSION 
The DCTAQ is a new tool for use in clinical practice that was developed because of the clinical need 
for close monitoring of chemotherapy toxicity and in recognition of the limitations of current available 
questionnaires (see Introduction section). Indeed, the DCTAQ is a comprehensive clinical tool, 
specifically developed for use in chemotherapy settings, that employs patient self-reporting and a 
short (past 24 hours) time window to capture patients’ experiences in relation to 10 core 
chemotherapy-related symptoms (plus any additional symptoms). Its brevity, short time-frame for 
recall, and embedded symptom descriptors make it appropriate for everyday use by patients 
receiving in-patient or outpatient chemotherapy to enable close and accurate symptom monitoring by 
the clinical team. As such, the DCTAQ can be seen as a means to mitigate current expressed 
concerns about the quality of chemotherapy toxicity assessments in clinical practice (Beijers, Mols, 
Van Den Hurk, & Vreugdenhil, 2016). 
 
Our findings support the content validity, feasibility/acceptability and stability of the DCTAQ in 
assessing chemotherapy toxicity in this sample of patients with breast or colorectal cancer. Content 
validity was maximised by capturing the perspectives of both patients and clinicians, in line with 
current literature that considers patient and clinician involvement as a key component in the 
development process to enhance the quality, applicability and acceptability of a PRO measure 
(Staniszewska et al., 2012), and to “ensure that the product has a coherent fit with the care process” 
(p. 1143) (Richardson, Medina, Brown, & Sitzia, 2007). To that end, participation of patients and 
clinicians from multiple clinical sites/regions across the UK ensured that a necessary level of 
diversity in individual educational (patients) and/or clinical backgrounds (health professionals) was 
reached. The success of this approach was reflected on the questionnaire’s documented 
feasibility/acceptability, given the absence of DCTAQ-related drop outs, the limited number of 
missing data and the reported high levels of item accuracy based on patient feedback during 
subsequent field testing. It is possible that the inclusion of CTCAE toxicity descriptors corresponding 
to three levels of symptom severity (mild, moderate and severe) may have contributed to such 
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favourable outcomes, owing perhaps to enhanced patient comprehension and interpretation of 
DCTAQ items. The wide subjectivity of the experience of cancer-related symptoms as well as the 
lack of integration between PRO-based grading and clinician-based grading  are recognised barriers 
to PRO-driven clinical assessments (National Institute of Cancer, 2009; Paice, 2004). We believe 
that DCTAQ addresses the clinical need for a unified assessment method to enhance patient-
clinician communication when it comes to chemotherapy toxicity assessment. 
 
As an indicator of internal consistency, the KR-20 was only modest (0.56), given that values closer to 
1 indicate higher internal consistency (Kuder & Richardson, 1937). A number of factors may have 
contributed to this modest coefficient, including a small number of items on the DCTAQ, a relatively 
small sample size, low variability in participants’ responses, or testing a body of content that was not 
unified (i.e. assessment of symptom prevalence, but with different bio-behavioural symptom triggers 
that could affect prevalence of individual symptoms). Further investigation is required to confidently 
establish internal consistency of the DCTAQ.  
 
The DCTAQ, however, does appear to have very good test-retest reliability when administered at 1-
hour intervals, with κ coefficients for the total sample and cancer type subgroups exceeding cut-offs 
for excellent agreement (>0.80) for most of its items, and irrespective of type of cancer, gender or 
age. Still, a number of items were found to have lower levels of agreement. It is perhaps not 
surprising that for patients with breast cancer lower levels of agreement were observed for items 
such as ‘feeling sick’ and ‘sore mouth and/or throat’ as these toxicities have a rapid trajectory and 
can change over a relatively short period of time. Items such as ‘changes in sensation in hands 
and/or feet’ and ‘sore hands and feet’ were associated with lower levels of agreement for patients 
with colorectal cancer. This again may be a reflection of the trajectory of cutaneous and sensory 
toxicities associated with many of the chemotherapy regimens administered to this patient group 
(Driessen, de Kleine-Bolt, Vingerhoets, Mols, & Vreugdenhil, 2012; Nagore, Insa, & Sanmartin, 
2000). 
 
Recently, Beijers et al. (2016) proposed clinical use of an index to quantify the “burden of treatment” 
and allow clinicians to make prompt decisions, e.g. about modifying the chemotherapy protocol. 
Their view was that burden of treatment is expressed as a composite score that takes into account 
the number and severity of chemotherapy toxicity as well as the number of days between 
chemotherapy cycles that patients experienced said toxicity. To this direction, Beijers et al. 
recognised the absence of a fit-for-purpose tool (Beijers et al., 2016). DCTAQ seems to address this 
gap, and further research is warranted to examine whether such index score might be a useful 
addition in clinical practice.  
 
Finally, with the advent of digital solutions such as mobile phone technology or tablet personal 
computers (Bennett, Jensen, & Basch, 2012), development of electronic versions PRO measures 
(ePRO measures) are expected to promote ‘real-time’ symptom monitoring and allow greater 
flexibility in symptom management in terms of remote monitoring and symptom alerting (Gilbert et 
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al., 2015). Following development of the DCTAQ, our group carried on to create the e-DCTAQ, the 
electronic equivalent of the DCTAQ for use with mobile phones and smartphones (to be reported on 
a separate publication). Briefly, symptom monitoring via the e-DCTAQ was coupled with the 
development of risk algorithms and an alerting system that, whenever a symptom was reported as 
exceeding a pre-determined cut-point, generated and sent alerts to acute care clinicians for action 
(Maguire et al., 2017).  
 
Limitations 
Some limitations in this study warrant comment. Although data were gathered from multiple clinical 
sites, our sample consisted of patients with good use of English, whereas almost no patients were 
from ethnic minority backgrounds. Our relatively small sample size also limits statistical power of our 
tests and may have prevented diversity in the patients’ symptom profiles. With regard to content 
validity of the DCTAQ, during the initial development stages, medical oncologists were invited to 
review the pilot DCTAQ, but no responses were received. Despite this limitation, we believe that our 
rigorous investigation of the literature and involvement of cancer care experts in successive review 
rounds has led to a PRO measure, whose status seems to be in line with medical oncologists’ views 
and priorities for symptom reporting in clinical practice. Since initial development of the DCTAQ, we 
have embarked on additional work involving the DCTAQ (Maguire et al., 2017) and consultation with 
oncologists from around the world, who have commented positively on the content format of this 
PRO measure. Moreover, psychometric properties of the DCTAQ were investigated with patients 
with breast or colorectal cancer; hence, our findings might not apply to groups of patients with other 
types of cancer. Our goal was to provide clinicians with a chemotherapy toxicity assessment tool, 
whose properties may be transferrable to other cancer patient populations. Nevertheless, future 
research will need to be inclusive of patient samples with different types of cancer receiving diverse 
chemotherapy regimens. Along these lines, formatting of items and scale responses was similar to 
that of two widely established symptom assessment questionnaires, the Memorial Symptom 
Assessment Scale (Portenoy et al., 1994) and the Rotterdam Symptom Checklist (de Haes et al., 
1996); this might be seen as a point in favour of validity, but definitely cannot be used to draw 
conclusions on the construct validity of the DCTAQ that will need to be confirmed in the near future. 
Finally, due possibly to the formation of our convenience study sample, who as per the parent 
study’s protocol were involved in the test/retest exercise during their first chemotherapy cycle to 
reduce unnecessary burden, reporting of some chemotherapy-related symptoms was rather 
infrequent. This finding may not reflect the symptom experience of all patients and throughout the 
treatment phase, and may have contributed to the low variability in responses received on the 
DCTAQ.  
 
CONCLUSIONS 
In sum, we developed and tested a new clinical assessment tool for chemotherapy toxicity, whose 
goal is to allow timely identification of patients requiring comprehensive symptom management and 
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care during chemotherapy. Our findings demonstrate that the DCTAQ is highly relevant, and it can 
be easily incorporated in clinical practice and used daily by patients treated with chemotherapy. The 
DCTAQ has strong content validity and stability, while its additional feature of severity descriptors to 
enhance interpretation and reporting accuracy can enhance patient-clinician communication in 
favour of prompt symptom management. Future research in the psychometric properties of the 
DCTAQ will require replicating its internal consistency and stability, as well as exploring its construct 
validity. This work will require larger and more diverse patient samples, involvement of patients with 
types of cancer other than breast or colorectal, and patients at different stages of chemotherapy and 
with diverse chemotherapy protocols. 
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TABLES 
Table 1. Characteristics of the study participants 
Characteristic 
Total sample 
(n=82) 
Colorectal cancer 
group (n=34) 
Breast cancer 
group (n=48) 
Mean±SD 
(min-max) 
Mean±SD 
(min-max) 
Mean±SD 
(min-max) 
Age (years) 55.8±10.8 
(29-75) 
59.9±9.5 
(43-74) 
52.9±10.8 
(29-75) 
 n (%) n (%) n (%) 
Gender 
Male 
Female 
 
18 (22.0) 
64 (78.0) 
 
18 (52.9) 
16 (47.1) 
 
0 (0) 
48 (100) 
Stage of disease (UICC/TNM) 
0 
I 
II 
III 
IV 
 
1 (1.2) 
13 (15.9) 
20 (24.4) 
47 (57.3) 
1 (1.2) 
 
0 (0.0) 
2 (5.9) 
6 (17.6) 
25 (73.5) 
1 (2.9) 
 
1 (2.1) 
11 (22.9) 
14 (29.2) 
22 (45.8) 
0 (0.0) 
Chemotherapy Regimen 
Oxaliplatin/De-Gramont 
De-Gramont 
Capecitabine 
Oxaliplatin/Capecitabine  
Capecitabine/De-Gramont 
FEC 
FEC-T 
AC 
Docetaxel 
FEC-T-H 
Docetaxel/Cyclophosphamide 
  
16 (47.1) 
2 (5.9) 
5 (14.7) 
9 (26.4) 
2 (5.9) 
 
 
 
 
 
 
33 (68.7) 
10 (20.8) 
1 (2.1) 
1 (2.1) 
2 (4.2) 
1 (2.1) 
Abbreviations: FEC – Fluorouracil, Epirubicin, Cyclophosphamide; AC – Adriamycin, Cyclophosphamide; FEC-T – 
Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel; FEC-T-H – Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel, 
Trastuzumab; De-Gramont – Folinic Acid, Fluorouracil; SD – Standard deviation 
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Table 2. Agreement in terms of κ statistic between the same questions asked 1 hour apart for the total sample (n=82) and for breast cancer 
patients (n=48) and colorectal cancer patients (n=34) 
 Total sample Breast Cancer Colorectal Cancer 
CTAQ Item 
Symptom 
prevalence 
n (%) 
%
 
A
g
r
e
e
m
e
n
t
 
κ
 
(
S
E
)
 
Symptom 
prevalence 
n (%) 
%
 
A
g
r
e
e
m
e
n
t
 
κ
 
(
S
E
)
 
Symptom 
prevalence 
n (%) 
%
 
A
g
r
e
e
m
e
n
t
 
κ
 
(
S
E
)
 
Time 1 Time 2 Time 1 Time 2 Time 1 Time 2 
1. Feeling sick 4 (4.9) 3 (3.7) 98.8 0.85 (0.15) 2 (4.2%) 1 (2.1%) 97.9 0.66 (0.33) 2 (5.9%) 2 (5.9%) 100 1.00 (0.0) 
2. Being sick 0 (0.0) 0 (0.0) 100 NA 0 (0%) 0 (0%) 100 NA 0 (0%) 0 (0%) 100 NA 
3. Diarrhoea 4 (4.9) 4 (4.9) 100 1.00 (0.0) 1 (2.1%) 1 (2.1%) 100 1.00 (0.0) 3 (8.8%) 3 (8.8%) 100 1.00 (0.0) 
4. Constipation 2 (2.4) 2 (2.4) 100 1.00 (0.0) 1 (2.1%) 1 (2.1%) 100 1.00 (0.0) 1 (2.9%) 1 (2.9%) 100 1.00 (0.0) 
5. Sore mouth/throat 8 (9.8) 7 (8.5) 96.3 0.78 (0.12) 4 (8.3%) 2 (4.2%) 95.8 0.64 (0.23) 4 (11.8%) 5 (14.7%) 97.1 0.87 (0.05) 
6. Changes in sensation in 
your hands and/or feet 
21 (25.6) 19 (23.2) 95.1 0.87 (0.06) 5 (10.4%) 5 (10.4) 100 1.00 (0.0) 16 (47.1%) 14 (41.2%) 88.2 0.76 (0.11) 
7. Sore hands and/or feet 7 (8.5) 7 (8.5) 97.6 0.84 (0.11) 2 (4.2%) 2 (4.2%) 100 1.00 (0.0) 5 (14.7%) 5 (14.7%) 94.1 0.77 (0.16) 
8. Flu-like 
symptoms/infection 
6 (7.3) 7 (8.5) 100 1.00 (0.0) 4 (8.3%) 4 (8.3%) 100 1.00 (0.0) 2 (5.9%) 2 (5.9%) 100 1.00 (0.0) 
9. Tiredness 48 (58.5) 51 (62.2) 96.3 0.92 (0.04) 26 (54.2%) 29 (60.4%) 93.8 0.87 (0.07) 22 (64.7%) 22 (64.7%) 100 1.00 (0.0) 
10. Pain 24 (29.7)* 23 (28.4)* 96.3* 0.91 (0.05) 9 (18.8%) 8 (16.7%) 97.9 0.93 (0.07) 15 (44.1%) 15 (44.1%) 93.9** 0.89 (0.08) 
Notes: NA – questions all answered ‘No’ so κ could not be calculated. 
Abbreviations: SE – Standard error 
*n=81; **n=33 
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Table 3. Agreement in terms of κ statistic between the same questions asked 1 hour apart 
according to gender and age for patients with colorectal cancer, and according to age for 
patients with breast cancer. 
 Colorectal cancer Breast Cancer 
 Gender Age Age 
CTAQ Item 
Female 
(n=16) 
Male 
(n=18) 
<55 yrs 
(n=12) 
55+ yrs 
(n=22) 
<55 yrs 
(n=30) 
55+ yrs 
(n=18) 
κ (SE) κ (SE) κ (SE) κ (SE) κ (SE) κ (SE) 
1. Feeling sick 1.00 (0.33) 1.00 (0.0) 1.00 (0.0) NA 1.00 (0.33) NA 
2. Being sick NA NA NA NA NA NA 
3. Diarrhoea 1.00 (0.0) 1.00 (0.0) 1.00 (0.0) 1.00 (0.0) 1.00 (0.0) NA 
4. Constipation 1.00 (0.0) NA 1.00 (0.0) NA NA NA 
5. Sore mouth/throat 1.00 (0.0) 0.77 (0.22) 1.00 (0.0) 0.64 (0.33) 1.00 (0.0) 0.63 (0.33) 
6. Changes in sensation in 
your hands and/or feet 
0.87 (0.13) 0.64 (0.18) 0.86 (0.14) 0.68 (0.17) 1.00 (0.0) 1.00 (0.0) 
7. Sore hands and/or feet 0.63 (0.33) 0.82 (0.17) 1.00 (0.0) 0.60 (0.25) 1.00 (0.0) NA 
8. Flu-like 
symptoms/infection 
1.00 (0.0) 1.00 (0.0) 1.00 (0.0) NA 1.00 (0.0) NA 
9. Tiredness 1.00 (0.0) 1.00 (0.0) 1.00 (0.0) 1.00 (0.0) 0.86 (0.10) 0.87 (0.13) 
10. Pain 0.88 (0.12)* 0.88 (0.17) 0.85 (0.14) 0.89 
(0.10)** 
0.90 (0.10) 1.00 (0.0) 
Notes: NA – questions all answered ‘No’ so κ could not be calculated. 
Abbreviations: SE – Standard error 
*n=15; **n=21 
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